A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia

International Journal of Neuroscience

Volumn 128, Issue 7, 2018, Pages 619-626

  Lew, Mark F ^a   Brashear, Allison ^b   Dashtipour, Khashayar ^c   Isaacson, Stuart ^d   Hauser, Robert A ^e   Maisonobe, Pascal ^f   Snyder, Daniel ^f   Ondo, William ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Parkinson's Disease and Movement Disorder Center of Boca Raton   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f IPSEN   (France)

^g HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

AbobotulinumtoxinA; cervical dystonia; onabotulinumtoxinA; spasmodic torticollis; TWSTRS

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; ARTICLE; BLURRED VISION; BRONCHITIS; BURNING SENSATION; CERVICAL DYSTONIA; COLON TUMOR; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DILUTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ENDOMETRIUM CANCER; FATIGUE; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE WEAKNESS; NECK PAIN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINUSITIS; TRANSIENT ISCHEMIC ATTACK; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; TORTICOLLIS; TREATMENT OUTCOME;

ACETYLCHOLINE RELEASE INHIBITORS; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; TORTICOLLIS; TREATMENT OUTCOME;

EID: 85041119101     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207454.2017.1406935     Document Type: Article

References (20)

1. Jinnah HA, Berardelli A, Comella C, et al. The focal dystonias: current views and challenges for future research. Mov Disord. 2013;28(7):926–943.
2. Dashtipour K, Lew M. Cervical dystonia. In: Stacy M, editor. Handbook of dystonia. 2nd ed. London (UK): Informa Healthcare; 2012. p. 144–158.
3. Benecke R, Frei K, Comella C. Treatment of cervical dystonia. In: Truong D, Dressler D, Hallett M, editors. Manual of botulinum toxin therapy. Cambridge: Cambridge Univerisity Press; 2009. p. 29–42.
4. Defazio G, Jankovic J, Giel JL, et al. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (NY). 2013;3:tre-03-193-4374-2 doi:10.7916/D80C4TGJ
5. DYSPORT® for injection (abobotulinumtoxinA) [prescribing information]. Basking Ridge (NJ): Ipsen Biopharmaceuticals, Inc.; July, 2016.
6. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783–791.
7. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316–323.
8. Hauser RA, Truong D, Hubble J, et al. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm. 2013;120(2):299–307.
9. Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015;262(10):2201–2213.
10. Jost WH, Hefter H, Stenner A, et al. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J Neural Transm (Vienna). 2013;120(3):487–496.
11. Consky E, Basinski A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale TWSTRS assessment of validity and inter-rater reliability [abstract]. Neurology. 1990;40(suppl 1)(4):445.
12. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439–1446.
13. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431–1438.
14. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510–517.
15. Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1–2):103–109.
16. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949–1951.
17. BOTOX COSMETIC (onabotulinumtoxinA) for injection, for intramuscular use [prescribing information]. Irvine (CA): Allergan, Inc.; January, 2016.
18. Rystedt A, Nyholm D, Naver H. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia. Clin Neuropharmacol. 2012;35(6):278–282.
19. Dashtipour K, Chen JJ, Espay AJ, et al. OnabotulinumtoxinA and AbobotulinumtoxinA dose conversion: a systematic literature review. Mov Disord Clin Pract. 2016;3(2):109–115.
20. Bentivoglio AR, Ialongo T, Bove F, et al. Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci. 2012;33(2):261–267.